The global autosomal dominant polycystic kidney disease (ADPKD) treatment market is driven by the increasing prevalence of the disease and advancements in treatment options. ADPKD is one of the most common genetic disorders, affecting approximately 1 in 400 to 1 in 1,000 live births worldwide. It is estimated that over 12 million people globally suffer from this condition. The disease leads to the progressive enlargement of cysts in the kidneys, often resulting in kidney failure by the age of 60 in around 50% of affected individuals. This highlights the need for effective treatments, including tyrosine kinase inhibitors such as Tolvaptan, which have shown promise in slowing disease progression. The growing burden of ADPKD is contributing to the increasing demand for therapies that address both the underlying causes and the symptoms of the disease, including hypertension and cyst growth, further stimulating market growth. Additionally, with improved awareness and diagnosis, the number of diagnosed cases is expected to rise, further fueling the demand for therapeutic interventions.
